# ClinicalTrials.gov record NCT03824002

> PeptideScanner retained ClinicalTrials.gov record NCT03824002 at 2026-07-30T20:57:18.709Z. Its registry update date was 2019-01-31, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03824002-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-01-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03824002-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03824002-dulaglutide-v1.json
- Content SHA-256: `2b025860162a06e277d7a1d84c7df9c5bac47d6287865808fe411b9c1b8508c3`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03824002 ([`ctg-observation-nct03824002-2019-01-31-166d2da9b45b`](#source-ctg-observation-nct03824002-2019-01-31-166d2da9b45b))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03824002 at 2026-07-30T20:57:18.709Z. Its registry update date was 2019-01-31, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct03824002-2019-01-31-166d2da9b45b`](#source-ctg-observation-nct03824002-2019-01-31-166d2da9b45b))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03824002 at 2026-07-30T20:57:18.709Z. Its registry update date was 2019-01-31, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct03824002-2019-01-31-166d2da9b45b`](#source-ctg-observation-nct03824002-2019-01-31-166d2da9b45b))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03824002-2019-01-31-166d2da9b45b`](#source-ctg-observation-nct03824002-2019-01-31-166d2da9b45b))

## Sources

<a id="source-ctg-observation-nct03824002-2019-01-31-166d2da9b45b"></a>
- **ClinicalTrials.gov record NCT03824002 · retained source version 2019-01-31:166d2da9b45bafbaa857bc0f09d4db7f1adf3c9968eff9193eef3d40cd307af9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03824002) (`ctg-observation-nct03824002-2019-01-31-166d2da9b45b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03824002." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03824002-dulaglutide-v1.json SHA-256: 2b025860162a06e277d7a1d84c7df9c5bac47d6287865808fe411b9c1b8508c3.